Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Updates on Acquisition

 In furtherance to our earlier intimation dated 30th April 2021, we wish to inform you that the National Company Law Tribunal, Mumbai vide its order dated 22nd June 2023 (certified copy of which was received on 19th July 2023), has approved the schemes of amalgamtion for merger of Pharmasofttech Awacs Private Limited into Pharmarack Technologies Private Limited. Both these Companies are subsidiaries of Aarogya Bharat Digital LLP (earlier known as DigiHealth Technologies LLP), which in turn is the wholly-owned subsidiary of ABCD Technologies LLP. The Company owns 6.45% interest in ABCD Technologies LLP. Request you to kindly take the same on record.
20-07-2023
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Newspaper Advertisement for transfer of equity shares to IEPF Authority
10-07-2023
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Newspaper Advertisement of Postal Ballot Notice.
06-07-2023
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

 Intimation regarding notice of Postal Ballot
05-07-2023
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Update On The Company''s Monroe, North Carolina (USA) Facility

 We refer to our letter dated 23rd August 2022 informing you about the 'Official Action Indicated' OAI status of the Company's Monroe, North Carolina (USA) manufacturing facility by US FDA following the US FDA inspection conducted between April 04 to May 19, 2022. We wish to inform you that the US FDA has now issued a warning letter to the Monroe facility. The Company had done a voluntary recall of all its products from this site in August 2021 and since then has not been commercializing any product from this site. Hence, the warning letter will have no impact on the existing revenues. Glenmark continues to cooperate with the US FDA and is committed to undertake all necessary steps required to address their observations at the earliest. The Company is committed to maintaining the highest quality and compliant manufacturing standards at all of its facilities across the globe.
21-06-2023

Glenmark Pharma slashes price of breast cancer drug Trastuzumab

 Glenmark Pharmaceuticals Ltd on Thursday said it has slashed the price of breast cancer drug Trastuzumab by bringing its brand Trumab at Rs 15,749 for a 440 mg vial from Rs 54,000 earlier. Trastuzumab is used in the treatment of a particular type of breast cancer -- HER2-positive, and the company markets its version in India under the brand name 'Trumab'. "The new price of the drug being marketed under the brand name 'Trumab', will be Rs 15,749 per 440 mg vial. This price reduction will bring the per mg cost of Trumab to around Rs 35, making it the most affordable treatment option for HER2-positive breast cancer in the country," Glenmark said in a statement. Most of the existing Trastuzumab brands in the market are priced in between Rs 40,000 to Rs 54,000 per 440 mg vial, the company said, adding the cost of Trastuzumab treatment has been a major barrier for many patients in India. "Considering that a patient needs to undergo a minimum of 18 cycles (12 months) of treatment, the...
15-06-2023
Bigul

Stock to buy today: Glenmark Pharmaceuticals (630.90)

 Accumulate on dips at 615
07-06-2023
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Glenmark Pharmaceuticals Ltd. Becomes A Part Of The Science Based Targets Initiative, Sets GHG Emission Targets For FY2035

 Glenmark Pharmaceuticals Ltd. (Glenmark), an integrated, research-led, global pharmaceutical company, reaffirms its commitment to sustainability by joining the esteemed Science Based Targets initiative (SBTi) business ambition for well below 2degC. The SBTi''s has approved Glenmark's commitment to reduce its absolute scope 1 and 2 GHG emissions by 35% (from a FY2021 base year) by FY2035. The target boundary includes biogenic land-related emissions and removals from bioenergy feedstock. The approval also extends to our pledge to reduce scope 3 GHG emissions from purchased goods and services, fuel and energy related activities, downstream transportation and distribution, and investments by 28% per ton of pharmaceutical products within the same timeframe. Glenmark got certified following a rigorous 5-stage review, and is only the second Indian Pharmaceutical company to receive this approval.
31-05-2023
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Compliances-Reg.24(A)-Annual Secretarial Compliance

 Annual Secretarial Compliance Report for the year ended 31st March, 2023
25-05-2023
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

 Transcript of the Earnings Call
25-05-2023
Next Page
Close

Let's Open Free Demat Account